



US00D588200S

(12) **United States Design Patent**
Langan et al.

(10) **Patent No.:** **US D588,200 S**
(45) **Date of Patent:** **** Mar. 10, 2009**

(54) **DRUG ADMINISTRATION SAFETY LABEL**

(75) Inventors: **Amy E. Langan**, Glenview, IL (US);
Richard J. Kruzynski, Long Grove, IL (US);
John A. Kollar, Northbrook, IL (US);
Patricia L. Miyake, Mundelein, IL (US);
Monique L. Kruk, Burlington, WI (US);
Mark F. Wagner, Gurnee, IL (US)

(73) Assignee: **PharMEDium Services, LLC**, Lake Forest, IL (US)

(**) Term: **14 Years**

(21) Appl. No.: **29/298,328**

(22) Filed: **Dec. 3, 2007**

(51) **LOC (9) Cl.** **19-08**

(52) **U.S. Cl.** **D20/27**

(58) **Field of Classification Search** D20/10,
D20/11, 13, 22-24, 27, 99; 40/124.01, 124.02,
40/124.04, 299.01, 310, 325, 360, 326, 538,
40/541, 584, 594, 600, 630, 638; 206/63.3,
206/534; 283/56, 71, 81; 428/40.1, 40.2,
428/42.3, 914

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,065,343	A	12/1977	Stumpe	
D311,423	S *	10/1990	DeSantis	D20/22
D386,212	S *	11/1997	Lambert	D20/22
5,924,561	A *	7/1999	Baumgartner et al.	206/63.3
D432,176	S *	10/2000	Stevens et al.	D20/22

(Continued)

OTHER PUBLICATIONS

Syringe label for Atropine sulfate, known prior to Dec. 3, 2007, 1 page.

Label for alcohol preps, known prior to Dec. 3, 2007, 1 page.

IV bag label for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

Syringe label for Labetalol Hydrochloride, known prior to Dec. 3, 2007, 1 page.

(Continued)

Primary Examiner—Caron Veynar

Assistant Examiner—Mary Ann Calabrese

(74) *Attorney, Agent, or Firm*—Bell, Boyd & Lloyd LLP

(57) **CLAIM**

The ornamental design for drug administration safety label, as shown and described.

DESCRIPTION

FIG. 1 is a top plan view of a drug administrative safety label of our new design,

FIG. 2 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 3 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 4 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 5 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 6 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 7 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,


FIG. 8 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design,

FIG. 9 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design; and,

FIG. 10 is a top plan view of an alternative embodiment of a drug administrative safety label of our new design.

In the drawings, the broken lines represent environmental structure forming no part of the claimed design.

1 Claim, 10 Drawing Sheets



US D588,200 S

Page 2

U.S. PATENT DOCUMENTS

6,568,530 B2 5/2003 Takahashi et al.
D522,065 S * 5/2006 Greenstein D20/27
D550,287 S * 9/2007 Smart et al. D20/23
7,311,205 B2 * 12/2007 Adler et al. 206/534
2007/0029788 A1 * 2/2007 Adler 283/81
2007/0252378 A1 * 11/2007 Chambers 283/81

OTHER PUBLICATIONS

Label for drug vial for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

Syringe label for Calcium Chloride, known prior to Dec. 3, 2007, 1 page.

Drug delivery device label for Phenylephrine, known prior to Dec. 3, 2007, 1 page.

Label for drug vial for Phenylephrine, known prior to Dec. 3, 2007, 1 page.

IV bag label for Fentanyl and Ropivacaine, known prior to Dec. 3, 2007, 1 page.

Label for drug vial for Vecuronium Bromide, known prior to Dec. 3, 2007, 1 page.

* cited by examiner

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : Des. 588,200 S
APPLICATION NO. : 29/298328
DATED : March 10, 2009
INVENTOR(S) : Langan et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

TITLE PAGE:

Title Page, Fig. 2, change "drug administrative" to --drug administration--.

Title Page, Fig. 3, change "drug administrative" to --drug administration--.

Title Page, Fig. 4, change "drug administrative" to --drug administration--.

Title Page, Fig. 5, change "drug administrative" to --drug administration--.

Title Page, Fig. 6, change "drug administrative" to --drug administration--.

Title Page, Fig. 7, change "drug administrative" to --drug administration--.


Title Page, Fig. 8, change "drug administrative" to --drug administration--.

Title Page, Fig. 9, change "drug administrative" to --drug administration--.

Title Page, Fig. 10, change "drug administrative" to --drug administration--.

Signed and Sealed this

First Day of September, 2009



David J. Kappos
Director of the United States Patent and Trademark Office